Cathay Biotech Receivables

The latest receivables for 688065.SS is $1.2B as of June 2026. That compares with $570M in the prior-year period — up 106.9% year over year. Investors often review this figure alongside Cathay Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 688065.SS's receivables moved from $570M to $1.2B — a 106.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cathay Biotech's operating scale or balance-sheet position.

A receivables figure of $1.2B for 688065.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 688065.SS's receivables ($1.2B), review year-over-year change from $570M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.